Taysha Gene Therapies (TSHA)
(Delayed Data from NSDQ)
$1.53 USD
-0.16 (-9.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $1.54 +0.01 (0.65%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Industry / Sector Report
Industry : Medical - Generic Drugs
Zacks Industry Rank
Top 20% (49 out of 250)Zacks Sector Rank
Top 19% (3 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.08 | 1.83 | 9.99 |
Current Quarter Estimate | -0.08 | 1.59 | 63.00 |
Year Ago Quarter Estimate | -0.13 | -0.94 | 52.25 |
Next Quarter Estimate | -0.08 | 1.73 | 66.00 |
Next Year Estimate | -0.38 | 6.80 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 63.54 | 21.90 | 15.67 |
Next Year | -8.57 | 5.90 | 11.34 |
Last 5 Years | NA | 0.10 | 8.10 |
Next 5 Years | NA | 13.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 51.00 | 3.43 |
Price/Book (MRQ) | 2.63 | 2.07 |
Price/Cash Flow (MRFY) | NA | 10.44 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -888.18% | NA |
Return on Equity (TTM) | -168.91% | NA |
Debt to Equity (MRQ) | NA | NA |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.